Artelo Biosciences raises $3 million in equity issuance and launches Solana reserve strategy

Nasdaq-listed Artelo Biosciences announced the issuance of 640,924 common shares to the public at $4.40 per share, raising about $3 million, according to Foresight News. Previously, Artelo Biosciences completed an over-the-counter private equity financing of US$9.475 million to launch a digital asset reserve strategy with Solana (SOL) as the core, becoming the first listed pharmaceutical company to include SOL in its reserve assets.